Innovotech Inc. Commences Trading on OTCQB Market, Expanding U.S. Investor Access

Innovotech Inc. announced that its common shares have commenced trading on the OTCQB Market in the United States under the symbol IOTCF, while continuing to trade on the TSX Venture Exchange under the symbol IOT. This development represents a strategic move to enhance engagement with U.S. investors as the company builds a larger, more diversified life sciences platform. Chief Executive Officer Craig Milne emphasized that listing on the OTCQB allows Innovotech to more effectively connect with the U.S. investment community during this growth phase.

The company reported strong operational progress and financial performance in 2025, with significant revenue increases driven by both organic growth and the full-year contribution from the acquisition of Keystone Labs Inc., executed in November 2024. Innovotech delivered consistent revenues across all quarters, reflecting improved scale, operational execution, and a more diversified revenue base. The successful integration of Keystone into operations materially expanded analytical chemistry and testing capabilities while strengthening the Canadian customer base. Following year-end, the company completed the amalgamation of its operating entities, simplifying its corporate structure and positioning the business as a single, integrated laboratory platform.

Innovotech strengthened its balance sheet through the exercise of warrants and the issuance of a convertible debenture, providing additional capital to support equipment purchases, operational expansion, and strategic initiatives. The company invested meaningfully in laboratory infrastructure, removing capacity bottlenecks and expanding technical capabilities through the acquisition of advanced analytical and microbiology equipment. Innovotech's differentiation is rooted in its depth of expertise in antimicrobial testing and biofilm-related research, supported by accredited quality systems and the ability to execute complex, custom testing programs. The company is frequently engaged on technically challenging projects requiring reproducibility, regulatory awareness, and close collaboration with client development teams, resulting in long-standing customer relationships and higher-value contract research work.

In addition to services, Innovotech manufactures and sells laboratory consumables, including its MBEC Assay® platform, which is used globally in biofilm and antimicrobial research. The company also maintains an active research and development program focused on expanding assay offerings and advancing proprietary technologies, including its InnovoSIL™ antimicrobial silver platform. As it enters 2026, Innovotech is focused on continued organic growth, expansion of service offerings, and disciplined execution of strategic priorities. The company is actively evaluating a pipeline of acquisition opportunities and continues to invest in infrastructure, people, and systems to support scale. Innovotech is expanding investor outreach efforts in the United States following its OTCQB listing, with Milne stating the company is building deliberately with focus on long-term value creation through operational excellence, differentiated capabilities, and disciplined growth. Learn more about the company at https://www.innovotech.ca and view the original release on https://www.newmediawire.com.